PRINCETON, N.J., April 16 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today data from a Phase 1/2 trial that suggest a potential association between higher doses of MDX-060, an investigational anti-CD30 antibody, and improvement in disease control and prolonged progression-free survival in patients with relapsed or refractory CD30- positive lymphomas. Results from the Phase 1/2 trial were presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego (Abstract #5525).
"We continue to assess the potential for anti-CD30 antibody therapies in the marketplace and are pleased with the findings of this exploratory study," said Howard H. Pien, President and CEO of Medarex. "We look forward to analyzing these results alongside the Phase 2 proof-of-concept chemotherapy combination data that is expected later in the year."
In the completed dose-escalation Phase 1/2 trial, 72 patients with
relapsed or refractory CD30-positive lymphoma received weekly doses of
MDX-060 (0.1, 1, 4, 10 or 15 mg/kg) for four weeks. Of the 33 patients
treated at the two highest doses of MDX-060, disease control was observed
in 51 percent of patients (3 complete responses, 14 stable disease), with
median progression- free survival of 3.7 months and 39 percent of patients
with no evidence of disease progression four months post-treatment. Of the
39 patients treated at the three lowest doses of MDX-060, disease control
was observed in 33 percent of patients (1 complete response, 2 partial
responses, 10 stable disease), with median progression-free survival of
less than 2 months and 18 percent of patients with no evidence of disease
progression four months post-treatment. MDX
|SOURCE Medarex, Inc.|
Copyright©2008 PR Newswire.
All rights reserved